Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Orthofix Medical (OFIX) over the last 16 years, with Q3 2025 value amounting to -$5.2 million.

  • Orthofix Medical's Cash from Financing Activities fell 10977.2% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year decrease of 3635.34%. This contributed to the annual value of $50.7 million for FY2024, which is 2237.07% down from last year.
  • Latest data reveals that Orthofix Medical reported Cash from Financing Activities of -$5.2 million as of Q3 2025, which was down 10977.2% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Orthofix Medical's Cash from Financing Activities peaked at $31.5 million during Q4 2024, and registered a low of -$7.6 million during Q2 2021.
  • In the last 5 years, Orthofix Medical's Cash from Financing Activities had a median value of $1.1 million in 2021 and averaged $5.7 million.
  • Per our database at Business Quant, Orthofix Medical's Cash from Financing Activities plummeted by 30117.12% in 2022 and then soared by 734246.03% in 2023.
  • Quarter analysis of 5 years shows Orthofix Medical's Cash from Financing Activities stood at $2.1 million in 2021, then decreased by 27.0% to $1.5 million in 2022, then skyrocketed by 1587.58% to $25.3 million in 2023, then increased by 24.55% to $31.5 million in 2024, then crashed by 116.36% to -$5.2 million in 2025.
  • Its Cash from Financing Activities stands at -$5.2 million for Q3 2025, versus $2.6 million for Q2 2025 and -$651000.0 for Q1 2025.